As of today (2026-06-28), the Forward Annual Dividend Yield of Cannara Biotech is 0.00%.
As of today (2026-06-28), the Trailing Annual Dividend Yield of Cannara Biotech is 0.00%.
TSX:LOVE's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.14 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Cannara Biotech Forward Dividend Yield % Related Terms
TSX:LOVE vs ZTS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Cannara Biotech (TSX:LOVE) has a Forward Dividend Yield % of 0.00% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Cannara Biotech and its competitors. According to the industry distribution chart, Cannara Biotech ranks #999999 out of 505 companies in the Drug Manufacturers industry.
Is Cannara Biotech's Forward Dividend Yield % too high?
Cannara Biotech's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Cannara Biotech ranks #999999 out of 505 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cannara Biotech has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Forward Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #999999 out of 505 companies for Forward Dividend Yield %. This places Cannara Biotech in the lower half of its industry. The industry median Forward Dividend Yield % is 2.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.14, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (TSX:LOVE) is currently considered Fairly Valued. The stock's GF Value™ is C$1.68, compared to a current price of C$1.68 — trading right at its estimated fair value. The current Forward Dividend Yield % is 0.00%. Cannara Biotech's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Cannara Biotech (TSX:LOVE), the current Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (TSX:LOVE) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be undervalued.
The current stock price of C$1.68 is trading 0% below its estimated GF Value™ of C$1.68.
GuruFocus considers Cannara Biotech to be Fairly Valued.
Key valuation signals for TSX:LOVE:
Forward Dividend Yield %: 0.00%
GF Value™: C$1.68 vs. price of C$1.68 (0% below fair value)
No single metric tells the full story. See the TSX:LOVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
92GF Score
Get the complete analysis for TSX:LOVE
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:LOVE has been successfully added to your 